Novavax, Inc. NVAX shares are trading lower by 3.05% to $58.43 Monday afternoon in sympathy with BioNTech SE - ADR BNTX, which reported worse-than-expected second-quarter results.
What Happened?
BioNTech believes the development of the pandemic remains dynamic, causing a re-phasing of orders and leading to fluctuations in quarterly revenues.
This revenue fluctuation caused by the re-phasing of orders is expected to remain over the rest of the financial year with uptake in demand in key markets in fourth-quarter FY22 related to the Omicron-adapted bivalent vaccine, subject to regulatory approval... Read More
According to data from Benzinga Pro, Novavax has a 52-week high of $277.80 and a 52-week low of $34.88.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
